The estimated Net Worth of Thomas A. Edwards is at least $9.34 Milion dollars as of 2 March 2021. Mr. Edwards owns over 1,100 units of ChemoCentryx Inc stock worth over $6,231,365 and over the last 9 years he sold CCXI stock worth over $2,856,882. In addition, he makes $256,533 as Independent Director at ChemoCentryx Inc.
Thomas has made over 10 trades of the ChemoCentryx Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he sold 1,100 units of CCXI stock worth $77,066 on 2 March 2021.
The largest trade he's ever made was buying 50,000 units of ChemoCentryx Inc stock on 17 May 2016 worth over $202,500. On average, Thomas trades about 9,009 units every 97 days since 2015. As of 2 March 2021 he still owns at least 119,857 units of ChemoCentryx Inc stock.
You can see the complete history of Mr. Edwards stock trades at the bottom of the page.
Thomas A. Edwards serves as Independent Director of the Company.D. serves as Independent Director of the Company. Until his retirement in March 2014, Mr. Edwards practiced law with Latham & Watkins LLP, an international law firm, since 1983, having become partner in January 1991. His practice focused on general corporate and securities law, including capital financings, acquisitions, divestitures and spin-offs of companies and partnerships. Mr. Edwards earned his bachelor’s degree from Harvard College and his law degree from Harvard Law School.
As the Independent Director of ChemoCentryx Inc, the total compensation of Thomas Edwards at ChemoCentryx Inc is $256,533. There are 9 executives at ChemoCentryx Inc getting paid more, with Thomas Schall having the highest compensation of $3,341,860.
Thomas Edwards is 61, he's been the Independent Director of ChemoCentryx Inc since 2015. There are 4 older and 9 younger executives at ChemoCentryx Inc. The oldest executive at ChemoCentryx Inc is Henry McKinnell, 77, who is the Independent Director.
Thomas's mailing address filed with the SEC is C/O CHEMOCENTRYX, INC., 835 INDUSTRIAL ROAD, SUITE 600, SAN CARLOS, CA, 94070.
Over the last 13 years, insiders at ChemoCentryx Inc have traded over $355,980,520 worth of ChemoCentryx Inc stock and bought 3,166,975 units worth $19,475,662 . The most active insiders traders include Plc Gsk, Rishi Gupta a (International) Ltd Vifor P.... On average, ChemoCentryx Inc executives and independent directors trade stock every 12 days with the average trade being worth of $4,175,785. The most recent stock trade was executed by Susan M Kanaya on 16 August 2022, trading 19,898 units of CCXI stock currently worth $216,092.
ChemoCentryx is a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. ChemoCentryx's lead drug candidate, avacopan (CCX168), successfully completed a pivotal Phase III trial in ANCA-associated vasculitis and a New Drug Application is under review by the U.S. Food and Drug Administration. Avacopan is also in late stage clinical development for the treatment of severe Hidradenitis Suppurativa and C3 glomerulopathy (C3G). ChemoCentryx also has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.
ChemoCentryx Inc executives and other stock owners filed with the SEC include: